Skip to main content
icon for Will Pfizer (PFE) beat quarterly earnings?
Finanzas·Acciones

Will Pfizer (PFE) beat quarterly earnings?

icon for Will Pfizer (PFE) beat quarterly earnings?
Finanzas·Acciones

Will Pfizer (PFE) beat quarterly earnings?

96% probabilidad
Polymarket
NUEVO
96% probabilidad
Polymarket
NUEVO
As of market creation, Pfizer is estimated to release earnings on May 5, 2026. The Street consensus estimate for Pfizer’s non-GAAP EPS for the relevant quarter is $0.72 as of market creation. This market will resolve to "Yes" if Pfizer reports non-GAAP EPS greater than $0.72 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Pfizer releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS. Pfizer's (PFE) 95.5% market-implied probability of beating Q1 2026 consensus non-GAAP EPS of approximately $0.72 reflects trader consensus built on the company's consistent earnings outperformance, including a 16% beat in Q4 2025 ($0.66 actual vs. $0.57 expected) and three beats in the last four quarters averaging 30% above estimates. Aggressive $7.7 billion cost savings through 2027 are enhancing margins as lower-margin COVID products like Comirnaty and Paxlovid fade, offset by growth in oncology (Padcev, Lorbrena), Prevnar, and Eliquis. Recent ASCO 2026 data highlighted pipeline strength. Tail risks include steeper COVID residuals or early patent cliff pressures on Eliquis, with resolution May 5 pre-market.

As of market creation, Pfizer is estimated to release earnings on May 5, 2026. The Street consensus estimate for Pfizer’s non-GAAP EPS for the relevant quarter is $0.72 as of market creation. This market will resolve to "Yes" if Pfizer reports non-GAAP EPS greater than $0.72 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.

If Pfizer releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)

If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”

Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Volumen
$648
Fecha de finalización
5 may 2026
Mercado abierto
Apr 23, 2026, 4:57 PM ET

Fuente de resolución

https://seekingalpha.com/

Resolver

0x65070BE91...
As of market creation, Pfizer is estimated to release earnings on May 5, 2026. The Street consensus estimate for Pfizer’s non-GAAP EPS for the relevant quarter is $0.72 as of market creation. This market will resolve to "Yes" if Pfizer reports non-GAAP EPS greater than $0.72 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Pfizer releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
As of market creation, Pfizer is estimated to release earnings on May 5, 2026. The Street consensus estimate for Pfizer’s non-GAAP EPS for the relevant quarter is $0.72 as of market creation. This market will resolve to "Yes" if Pfizer reports non-GAAP EPS greater than $0.72 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Pfizer releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS. Pfizer's (PFE) 95.5% market-implied probability of beating Q1 2026 consensus non-GAAP EPS of approximately $0.72 reflects trader consensus built on the company's consistent earnings outperformance, including a 16% beat in Q4 2025 ($0.66 actual vs. $0.57 expected) and three beats in the last four quarters averaging 30% above estimates. Aggressive $7.7 billion cost savings through 2027 are enhancing margins as lower-margin COVID products like Comirnaty and Paxlovid fade, offset by growth in oncology (Padcev, Lorbrena), Prevnar, and Eliquis. Recent ASCO 2026 data highlighted pipeline strength. Tail risks include steeper COVID residuals or early patent cliff pressures on Eliquis, with resolution May 5 pre-market.

As of market creation, Pfizer is estimated to release earnings on May 5, 2026. The Street consensus estimate for Pfizer’s non-GAAP EPS for the relevant quarter is $0.72 as of market creation. This market will resolve to "Yes" if Pfizer reports non-GAAP EPS greater than $0.72 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents.

If Pfizer releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.)

If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”

Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Volumen
$648
Fecha de finalización
5 may 2026
Mercado abierto
Apr 23, 2026, 4:57 PM ET

Fuente de resolución

https://seekingalpha.com/

Resolver

0x65070BE91...
As of market creation, Pfizer is estimated to release earnings on May 5, 2026. The Street consensus estimate for Pfizer’s non-GAAP EPS for the relevant quarter is $0.72 as of market creation. This market will resolve to "Yes" if Pfizer reports non-GAAP EPS greater than $0.72 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the non-GAAP EPS listed in the company’s official earnings documents. If Pfizer releases earnings without non-GAAP EPS, then the market will resolve according to the non-GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve according to the GAAP EPS listed in the company’s official earnings documents; or, if not published there, according to the GAAP EPS provided by SeekingAlpha. If no GAAP EPS number is available from either source at that time, the market will resolve to “No.” (For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless it is not published, in which case it refers to basic GAAP EPS.) If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.” Note: Subsequent restatements, corrections, or revisions made to the initially announced non-GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024). Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for non-GAAP EPS. Note: All figures will be rounded to the nearest cent using standard rounding. Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS. Note: If multiple versions of non-GAAP EPS are published, the market will resolve according to the primary headline non-GAAP EPS number, which is typically presented on a diluted basis. If diluted is not published, then basic non-GAAP EPS will qualify. Note: All figures are expressed in USD, unless otherwise indicated. Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.

Cuidado con los enlaces externos.

Preguntas frecuentes

"Will Pfizer (PFE) beat quarterly earnings?" es un mercado de predicción en Polymarket donde los operadores compran y venden acciones de "Sí" o "No" según si creen que este evento ocurrirá. La probabilidad actual según la comunidad es 96% para "Yes". Por ejemplo, si "Sí" se cotiza a 96¢, el mercado colectivamente asigna una probabilidad de 96% de que este evento ocurra. Estas probabilidades cambian continuamente a medida que los operadores reaccionan a nuevos desarrollos e información. Las acciones del resultado correcto son canjeables por $1 cada una tras la resolución del mercado.

"Will Pfizer (PFE) beat quarterly earnings?" es un mercado recién creado en Polymarket, lanzado el Apr 23, 2026. Como mercado nuevo, esta es tu oportunidad de ser uno de los primeros operadores en establecer las probabilidades y las señales de precio iniciales del mercado. También puedes guardar esta página en marcadores para seguir el volumen y la actividad de trading a medida que el mercado gana tracción.

Para operar en "Will Pfizer (PFE) beat quarterly earnings?", simplemente elige si crees que la respuesta es "Sí" o "No". Cada lado tiene un precio actual que refleja la probabilidad implícita del mercado. Introduce tu cantidad y haz clic en "Operar". Si compras acciones de "Sí" y el resultado se resuelve como "Sí", cada acción paga $1. Si se resuelve como "No", tus acciones de "Sí" pagan $0. También puedes vender tus acciones en cualquier momento antes de la resolución para asegurar ganancias o limitar pérdidas.

La probabilidad actual para "Will Pfizer (PFE) beat quarterly earnings?" es 96% para "Yes". Esto significa que la comunidad de Polymarket actualmente cree que hay una probabilidad de 96% de que este evento ocurra. Estas probabilidades se actualizan en tiempo real basándose en operaciones reales, proporcionando una señal continuamente actualizada de lo que el mercado espera.

Las reglas de resolución para "Will Pfizer (PFE) beat quarterly earnings?" definen exactamente qué debe ocurrir para que cada resultado sea declarado ganador, incluyendo las fuentes de datos oficiales utilizadas para determinar el resultado. Puedes revisar los criterios de resolución completos en la sección "Reglas" en esta página sobre los comentarios. Recomendamos leer las reglas cuidadosamente antes de operar, ya que especifican las condiciones exactas, casos especiales y fuentes.